These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19190165)

  • 1. Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population.
    Uhrhammer N; Delort L; Bignon YJ
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):684-5. PubMed ID: 19190165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex.
    Hsu HM; Wang HC; Chen ST; Hsu GC; Shen CY; Yu JC
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2024-32. PubMed ID: 17932350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
    Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
    Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.
    Heikkinen K; Rapakko K; Karppinen SM; Erkko H; Knuutila S; Lundán T; Mannermaa A; Børresen-Dale AL; Borg A; Barkardottir RB; Petrini J; Winqvist R
    Carcinogenesis; 2006 Aug; 27(8):1593-9. PubMed ID: 16474176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of RAD50 in familial breast cancer predisposition.
    Tommiska J; Seal S; Renwick A; Barfoot R; Baskcomb L; Jayatilake H; Bartkova J; Tallila J; Kaare M; Tamminen A; Heikkilä P; Evans DG; Eccles D; Aittomäki K; Blomqvist C; Bartek J; Stratton MR; Nevanlinna H; Rahman N
    Int J Cancer; 2006 Jun; 118(11):2911-6. PubMed ID: 16385572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer.
    He M; Di GH; Cao AY; Hu Z; Jin W; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2012 May; 133(1):111-6. PubMed ID: 21811815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan C; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2018 Oct; 143(8):1935-1942. PubMed ID: 29726012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers.
    Wang X; Szabo C; Qian C; Amadio PG; Thibodeau SN; Cerhan JR; Petersen GM; Liu W; Couch FJ
    Cancer Res; 2008 Feb; 68(4):971-5. PubMed ID: 18281469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan.
    Khan RT; Siddique A; Shahid N; Khokher S; Fatima W
    Breast Cancer; 2018 May; 25(3):350-355. PubMed ID: 29368209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of making ends meet: mutations in genes and altered expression of proteins of the MRN complex and cancer.
    Dzikiewicz-Krawczyk A
    Mutat Res; 2008; 659(3):262-73. PubMed ID: 18606567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MRE11/RAD50/NBS1 complex destabilization in Lynch-syndrome patients.
    Alemayehu A; Fridrichova I
    Eur J Hum Genet; 2007 Sep; 15(9):922-9. PubMed ID: 17534377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MRN protein complex genes: MRE11 and RAD50 and susceptibility to head and neck cancers.
    Ziółkowska-Suchanek I; Mosor M; Wierzbicka M; Rydzanicz M; Baranowska M; Nowak J
    Mol Cancer; 2013 Sep; 12(1):113. PubMed ID: 24079363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
    Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
    Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited relevance of the CHEK2 gene in hereditary breast cancer.
    Dufault MR; Betz B; Wappenschmidt B; Hofmann W; Bandick K; Golla A; Pietschmann A; Nestle-Krämling C; Rhiem K; Hüttner C; von Lindern C; Dall P; Kiechle M; Untch M; Jonat W; Meindl A; Scherneck S; Niederacher D; Schmutzler RK; Arnold N
    Int J Cancer; 2004 Jun; 110(3):320-5. PubMed ID: 15095295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.